# COL6A2

## Overview
The COL6A2 gene encodes the collagen type VI alpha 2 chain, a vital component of the extracellular matrix (ECM) that plays a significant role in maintaining the structural integrity and mechanical properties of various tissues, including skeletal muscles, tendons, bone, and cartilage. The protein is categorized as a structural ECM protein and is involved in forming a network of beaded microfilaments that contribute to tissue stability and function. The alpha 2 chain, along with other collagen VI chains, forms heterotrimeric monomers that assemble into higher-order structures, crucial for ECM organization and cellular interactions. COL6A2 is implicated in several cellular processes, such as cell adhesion, survival, and homeostasis, and is essential for preventing apoptosis and regulating autophagy. Mutations in COL6A2 are linked to muscular and connective tissue disorders, including Bethlem myopathy and Ullrich congenital muscular dystrophy, highlighting its clinical significance (Cescon2015Collagen; Morel2023Retrospective; Lamandé2018Collagen).

## Structure
The COL6A2 gene encodes the alpha 2 chain of type VI collagen, a crucial component of the extracellular matrix. The protein structure includes a central short triple helical domain, approximately 335-336 amino acids long, characterized by repeating Gly-Xaa-Yaa sequences. This domain is flanked by large N- and C-terminal globular domains, each consisting of motifs around 200 amino acids that are homologous to von Willebrand factor type A domains (Fitzgerald2008Three; Bushby2013Collagen).

The quaternary structure of type VI collagen involves the assembly of three different peptide chains: α1(VI), α2(VI), and α3(VI), forming heterotrimeric monomers. These monomers further assemble into dimers and then into tetramers, which are stabilized by disulfide bonds. The tetramers are secreted and align end-to-end to form beaded microfibrils in the extracellular matrix (BERTINI2002Collagen; Bushby2013Collagen).

Post-translational modifications of the COL6A2 protein include hydroxylation and glycosylation, which are essential for its stability and function. The 260-kD polypeptide, part of the type VI collagen molecule, shows heterogeneity on SDS PAGE, likely due to glycosylation or other post-translational modifications (Engvall1986Molecular).

## Function
The COL6A2 gene encodes the alpha 2 chain of type VI collagen, a crucial component of the extracellular matrix (ECM) in various tissues, including skeletal muscles, tendons, bone, and cartilage. In healthy human cells, collagen VI forms a network of beaded microfilaments that maintain the structural integrity and mechanical properties of tissues (Cescon2015Collagen). It plays a significant role in linking muscle cells to the ECM by binding to other ECM components like collagen IV and perlecan, contributing to the basement membrane of myofiber endomysium (Cescon2015Collagen).

Collagen VI is involved in several cellular processes, including cell adhesion, survival, and homeostasis. It exerts cytoprotective roles by inhibiting apoptosis and oxidative damage, promoting cell differentiation, and maintaining stemness (Cescon2015Collagen; Castagnaro2021Autophagy). The protein is essential for the structural integrity and function of skeletal muscles, preventing spontaneous apoptosis and regulating autophagy (Cescon2015Collagen). It also plays a role in maintaining mitochondrial functionality and modulating autophagy, ensuring cellular homeostasis (Castagnaro2021Autophagy). The α2(VI) chain, encoded by COL6A2, is critical for the assembly and stability of collagen VI microfibrils, which are essential for maintaining the biomechanical properties of tissues (Lamandé2018Collagen).

## Clinical Significance
Mutations in the COL6A2 gene are associated with a range of muscular and connective tissue disorders, primarily Bethlem myopathy (BM) and Ullrich congenital muscular dystrophy (UCMD). These conditions are characterized by muscle weakness, joint contractures, and varying degrees of severity. BM typically presents with milder symptoms, while UCMD is more severe, often manifesting in early infancy (Briñas2010Early; Morel2023Retrospective).

The genetic heterogeneity of collagen VI-related myopathies is significant, with mutations in COL6A2 leading to both dominant and recessive forms of these disorders. For instance, the COL6A2:c.1970-9G>A variant is a common pathogenic mutation associated with a recessive form of COL6-RD, causing variable clinical presentations (Morel2023Retrospective). Other mutations, such as deep intronic deletions, can impair transcription and collagen VI expression, contributing to the complexity of diagnosing these conditions (Bovolenta2010Identification).

Late-onset limb-girdle muscular dystrophy has also been linked to a novel mutation in COL6A2, highlighting the diverse phenotypic spectrum associated with this gene (Jokela2019A). These findings underscore the importance of genetic analysis in understanding and diagnosing collagen VI-related disorders.

## Interactions
COL6A2, the alpha 2 chain of type VI collagen, is a crucial component of the extracellular matrix and participates in various protein interactions. It forms a heterotrimeric complex with COL6A1 and COL6A3, which is essential for the structural integrity and function of the extracellular matrix (Lamandé2018Collagen). This complex interacts with other extracellular matrix proteins, including fibronectin, proteoglycans, and matrilins, contributing to the anchoring of the basement membrane to the surrounding matrix (Lamandé2018Collagen). 

COL6A2 also binds to a range of cell surface receptors such as integrins (α1β1, α2β1, α3β1, α10β1, αvβ1), CSPG4 (NG2), ANTXR1 (TEM8), and ANTXR2 (CMG2), facilitating cell adhesion and signaling (Lamandé2018Collagen). These interactions are vital for maintaining tissue integrity and influencing cellular behavior. 

In the context of disease, COL6A2 has been implicated in various pathological conditions, including muscular dystrophies and cancer. Its interactions with other proteins and its role in the extracellular matrix make it a potential target for therapeutic interventions in these diseases (Lamandé2018Collagen).


## References


[1. (Briñas2010Early) Laura Briñas, Pascale Richard, Susana Quijano‐Roy, Corine Gartioux, Céline Ledeuil, Emmanuelle Lacène, Samira Makri, Ana Ferreiro, Svetlana Maugenre, Haluk Topaloglu, Göknur Haliloglu, Isabelle Pénisson‐Besnier, Pierre‐Yves Jeannet, Luciano Merlini, Carmen Navarro, Annick Toutain, Denys Chaigne, Isabelle Desguerre, Christine de Die‐Smulders, Murielle Dunand, Bernard Echenne, Bruno Eymard, Thierry Kuntzer, Kim Maincent, Michèle Mayer, Ghislaine Plessis, François Rivier, Filip Roelens, Tanya Stojkovic, Ana Lía Taratuto, Fabiana Lubieniecki, Soledad Monges, Christine Tranchant, Louis Viollet, Norma B. Romero, Brigitte Estournet, Pascale Guicheney, and Valérie Allamand. Early onset collagen vi myopathies: genetic and clinical correlations. Annals of Neurology, 68(4):511–520, October 2010. URL: http://dx.doi.org/10.1002/ana.22087, doi:10.1002/ana.22087. This article has 106 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1002/ana.22087)

[2. (Morel2023Retrospective) Victor Morel, Frédérique Audic, Charlotte Tardy, Annie Verschueren, Shahram Attarian, Karine Nguyen, Emmanuelle Salort-Campana, Martin Krahn, Brigitte Chabrol, and Svetlana Gorokhova. Retrospective clinical and genetic analysis of col6-rd patients with a long-term follow-up at a single french center. Frontiers in Genetics, December 2023. URL: http://dx.doi.org/10.3389/fgene.2023.1242277, doi:10.3389/fgene.2023.1242277. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fgene.2023.1242277)

[3. (Bushby2013Collagen) Kate M. D. Bushby, James Collins, and Debbie Hicks. Collagen Type VI Myopathies, pages 185–199. Springer Netherlands, December 2013. URL: http://dx.doi.org/10.1007/978-94-007-7893-1_12, doi:10.1007/978-94-007-7893-1_12. This article has 93 citations.](https://doi.org/10.1007/978-94-007-7893-1_12)

[4. (Cescon2015Collagen) Matilde Cescon, Francesca Gattazzo, Peiwen Chen, and Paolo Bonaldo. Collagen vi at a glance. Journal of Cell Science, January 2015. URL: http://dx.doi.org/10.1242/jcs.169748, doi:10.1242/jcs.169748. This article has 168 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1242/jcs.169748)

[5. (Bovolenta2010Identification) Matteo Bovolenta, Marcella Neri, Elena Martoni, Anna Urciuolo, Patrizia Sabatelli, Marina Fabris, Paolo Grumati, Eugenio Mercuri, Enrico Bertini, Luciano Merlini, Paolo Bonaldo, Alessandra Ferlini, and Francesca Gualandi. Identification of a deep intronic mutation in the col6a2 gene by a novel custom oligonucleotide cgh array designed to explore allelic and genetic heterogeneity in collagen vi-related myopathies. BMC Medical Genetics, March 2010. URL: http://dx.doi.org/10.1186/1471-2350-11-44, doi:10.1186/1471-2350-11-44. This article has 26 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/1471-2350-11-44)

[6. (Fitzgerald2008Three) Jamie Fitzgerald, Cathleen Rich, Fiona H. Zhou, and Uwe Hansen. Three novel collagen vi chains, α4(vi), α5(vi), and α6(vi). Journal of Biological Chemistry, 283(29):20170–20180, July 2008. URL: http://dx.doi.org/10.1074/jbc.M710139200, doi:10.1074/jbc.m710139200. This article has 206 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.M710139200)

[7. (BERTINI2002Collagen) ENRICO BERTINI and GUGLIELMINA PEPE. Collagen type vi and related disorders: bethlem myopathy and ullrich scleroatonic muscular dystrophy. European Journal of Paediatric Neurology, 6(4):193–198, July 2002. URL: http://dx.doi.org/10.1053/ejpn.2002.0593, doi:10.1053/ejpn.2002.0593. This article has 72 citations and is from a peer-reviewed journal.](https://doi.org/10.1053/ejpn.2002.0593)

[8. (Jokela2019A) Manu Jokela, Sara Lehtinen, Johanna Palmio, Anna-Maija Saukkonen, Sanna Huovinen, Anna Vihola, and Bjarne Udd. A novel col6a2 mutation causing late-onset limb-girdle muscular dystrophy. Journal of Neurology, 266(7):1649–1654, April 2019. URL: http://dx.doi.org/10.1007/s00415-019-09307-y, doi:10.1007/s00415-019-09307-y. This article has 10 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1007/s00415-019-09307-y)

[9. (Engvall1986Molecular) E Engvall, H Hessle, and G Klier. Molecular assembly, secretion, and matrix deposition of type vi collagen. The Journal of cell biology, 102(3):703–710, March 1986. URL: http://dx.doi.org/10.1083/jcb.102.3.703, doi:10.1083/jcb.102.3.703. This article has 198 citations.](https://doi.org/10.1083/jcb.102.3.703)

[10. (Castagnaro2021Autophagy) Silvia Castagnaro, Lisa Gambarotto, Matilde Cescon, and Paolo Bonaldo. Autophagy in the mesh of collagen vi. Matrix Biology, 100–101:162–172, June 2021. URL: http://dx.doi.org/10.1016/j.matbio.2020.12.004, doi:10.1016/j.matbio.2020.12.004. This article has 14 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.matbio.2020.12.004)

[11. (Lamandé2018Collagen) Shireen R. Lamandé and John F. Bateman. Collagen vi disorders: insights on form and function in the extracellular matrix and beyond. Matrix Biology, 71–72:348–367, October 2018. URL: http://dx.doi.org/10.1016/j.matbio.2017.12.008, doi:10.1016/j.matbio.2017.12.008. This article has 119 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.matbio.2017.12.008)